Skip to main content
Article thumbnail
Location of Repository

The use of antigen presenting cell/tumour cell hybrids for the in vitro induction of tumour-specific T cells

By Yehia Saleh Ahmed Mohamed


Malignant tumours are the second main cause of mortality worldwide, with haematological malignancies representing 10%. Current treatment strategies, such as chemotherapy, radiotherapy, and stem cell transplantation, are mostly effective but may induce serious side effects. In addition, tumours are developing resistance against most of these conventional therapies.\ud Immunotherapy is a promising investigational approach, especially hybrid cell vaccination, in which a professional APC is fused to a tumour cell, and the fusion product mostly combines the antigenicity of the tumour cell partner, processed and presented through the relevant APC-machinery, and associated with co-stimulatory molecules CD80, CD86, and CD40 expression, for proper induction of anti-tumour immune responses.\ud I investigated the phenotypic and functional characteristics of a group of previously-made hybrid cell lines, generated by in vitro fusion of a human APC (HMy2; EBV B-lymphoblastoid cell line) with haematological ex vivo or immortalized tumour cells.\ud On co-culture with allogeneic (normal donors) peripheral blood lymphocytes, hybrid cell lines induced elevated levels of T-cell proliferation compared with their relevant tumour cells, which was dependent on expression of co-stimulatory molecules CD80 and CD86, and MHC class I and class II antigens. The hybrid cell lines induced proliferation of naive, central memory, and effector memory populations of CD4+, CD8+ T-cells.\ud Moreover, the hybrid cells expressed a range of tumour associated antigens not expressed by HMy2 cells, or by normal PBMC. Depending on that, tumour-specific cytotoxic T lymphocytes were induced in vitro by stimulation of allogeneic or autologous PBMCs for multiple rounds with selected hybrid cell lines in the presence of rhIL-2. Tumour- and antigen-specificity of the activated T cells were assessed by IFN-γ releasing ELISpot, MHC class I (HLA-A2)-restricted tumour peptide-specific pentamer staining, and 51Cr-release cytotoxicity assays.\ud Hybrid cell vaccines generated in this way may therefore represent a novel strategy for use in immunotherapy of haematological malignancies, and possibly in other forms of cancer as well

Publisher: University of Leicester
Year: 2011
OAI identifier:

Suggested articles


  1. (2009). A critical analysis of the tumour immunosurveillance controversy for 3-MCA-induced sarcomas.
  2. (2004). A dendritic cell based hybrid cell vaccine generated by electrofusion for immunotherapy strategies in HNSCC.
  3. (2001). A fresh look at tumor immunosurveillance and immunotherapy.
  4. (1991). A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.
  5. (2000). A high number of tumor-infiltrating lymphocytes are associated with a small tumor size, low tumor stage, and a favorable prognosis in operated small cell lung carcinoma.
  6. (1982). A human-hybridoma system based on a fast-growing mutant of the ARH-77 plasma cell leukemia-derived line.
  7. (2005). A listing of human tumor antigens recognized by T cells:
  8. (2003). A new genetic method to generate and isolate small, short-lived but highly potent dendritic cell-tumor cell hybrid vaccines.
  9. (2005). A new murine tumor model for studying HLA-A2-restricted anti-tumor immunity.
  10. (2002). A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer.
  11. (2006). A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GMCSF and interferon-alpha in metastatic melanoma patients. Cancer Immunology, Immunotherapy :
  12. (1994). A quantitative analysis of antigen-presenting cell function: activated B cells stimulate naive CD4 T cells but are inferior to dendritic cells in providing costimulation.
  13. (1997). A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening.
  14. (2011). Abagovomab: an antiidiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer.
  15. (2008). About human tumor antigens to be used in immunotherapy.
  16. (2005). Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells.
  17. (1994). Activation of CD4+ T cells by delivery of the B7 costimulatory signal on bystander antigen-presenting cells (trans-costimulation).
  18. (1978). Acute myelogenous leukemia: a human cell line responsive to colony-stimulating activity.
  19. (2007). Adaptive immunity maintains occult cancer in an equilibrium state.
  20. (2010). Adaptive immunity.
  21. (2009). Adoptive cell therapy for the treatment of patients with metastatic melanoma.
  22. (2005). Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma.
  23. (2008). Adoptive cell transfer: a clinical path to effective cancer immunotherapy.
  24. (1996). Adoptive cellular immunotherapy of cancer in mice using allogeneic T-cells. Annals of Surgical Oncology.
  25. (1997). Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.
  26. (2007). Adoptive T cell therapy for cancer in the clinic.
  27. (2004). Adoptive transfer of allogeneic Epstein–Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma.
  28. Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation.
  29. (2010). Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma.
  30. (2010). Adoptive transfer of PR1 cytotoxic T lymphocytes associated with reduced leukemia burden in a mouse acute myeloid leukemia xenograft model.
  31. (2007). Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial.
  32. (2006). Allogeneic gastric cancer cell-dendritic cell hybrids induce tumor antigen (carcinoembryonic antigen) specific CD8+T cells.
  33. (2010). Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial.
  34. (2004). Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer.
  35. (2007). Allopeptides and the alloimmune response. Cellular Immunology.
  36. (2001). Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy.
  37. (2003). Antigen presentation by mouse CD4+ T cells involving acquired MHC class II:peptide complexes: another mechanism to limit clonal expansion.
  38. (1995). Antigen processing: The gateway to the immune response.
  39. Antigen-specific polyclonal cytotoxic T lymphocytes induced by fusions of dendritic cells and tumor cells.
  40. Antitumor vaccination: where we stand.
  41. (2005). Assessment of fusion cells from patient-derived ovarian carcinoma cells and dendritic cells as a vaccine for clinical use. Gynecologic Oncology.
  42. (2002). Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors.
  43. (2009). Autophagy and its role in MHC-mediated antigen presentation.
  44. (2008). Autophagy fights disease through cellular self-digestion.
  45. (2005). Autoreactive CD8+ T cells in multiple sclerosis: a new target for therapy.
  46. (1991). B cell phenotype-dependent expression of the Epstein-Barr virus nuclear antigens EBNA-2 to EBNA-6: studies with somatic cell hybrids.
  47. (1995). BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes.
  48. (2008). Basic immunology: functions and disorders of the immune system. 3rd ed.
  49. (2003). Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity.
  50. (2006). Cancer despite immunosurveillance: immunoselection and immunosubversion.
  51. (2002). Cancer immunoediting: from immunosurveillance to tumor escape.
  52. (2005). Cancer immunotherapy by fusions of dendritic and tumour cells and rh-IL-12.
  53. (2006). Cancer immunotherapy targeting the telomerase reverse transcriptase.
  54. (2002). Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?
  55. (2009). Cancer Immunotherapy. Topics in
  56. (2002). Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.
  57. (2009). Cancer vaccine by fusions of dendritic and cancer cells. Clinical & Developmental Immunology.
  58. (2004). Cancer vaccine development: on the way to break immune tolerance to malignant cells.
  59. (2002). Cancer vaccines and immunotherapy.
  60. (2009). Cancer/testis (CT) antigens: potential targets for immunotherapy.
  61. (2007). Cancertestis antigens in haematological malignancies.
  62. (2009). Cathepsin S regulates class II MHC processing in human CD4+ HLA-DR+ T cells.
  63. (2008). CD40 Ligand-activated, antigenspecific B cells are comparable to mature dendritic cells in presenting protein antigens and major histocompatibility complex class I- and class II-binding peptides.
  64. (1997). CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigenspecific T cells for adoptive immunotherapy.
  65. CD40-stimulated B Lymphocytes Pulsed with Tumor Antigens Are Effective Antigenpresenting Cells That Can Generate Specific T Cells.
  66. (2007). CD56brightCD16- Killer Ig-Like Receptor- NK Cells Display Longer Telomeres and Acquire Features of CD56dim NK Cells upon Activation.
  67. (1981). Cell fusion by Semliki Forest, influenza, and vesicular stomatitis viruses.
  68. (2004). Central memory and effector memory T cell subsets: function, generation, and maintenance. Annual Review of Immunology.
  69. (2005). Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells.
  70. (1999). Characterization of the GAGE genes that are expressed in various human cancers and in normal testis.
  71. (1997). Characterization of tumor-infiltrating lymphocytes derived from human tumors for use as adoptive immunotherapy of cancer.
  72. (1979). Chemical carcinogenesis in nude mice: comparison between nude mice from homozygous matings and heterozygous matings and effect of age and carcinogen dose.
  73. (2004). Class II MHC peptide loading by the professionals. Current Opinion in Immunology.
  74. (2010). Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients.
  75. (2003). Co-stimulatory members of the TNFR family: keys to effective T-cell immunity?
  76. (2010). Combating cancer with allogeneic T cells.
  77. (2011). Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma.
  78. (2001). Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice.
  79. (2004). Complement function in mAb-mediated cancer immunotherapy. Trends in Immunology.
  80. (2009). Complement-mediated tumour growth: Implications for cancer nanotechnology and nanomedicines.
  81. (2000). Complete spontaneous regression of cancer: four case reports, review of literature, and discussion of possible mechanisms involved.
  82. (2005). Concerted antigen presentation by dendritic cells and B cells is necessary for optimal CD4 T-cell immunity in vivo.
  83. (1995). Contribution of class I HLA-A2 antigen in immune reactions. Medical hypotheses.
  84. Costimulation via CD55 on Human CD4+ T Cells Mediated by CD97.
  85. (2005). Cross-presentation: underlying mechanisms and role in immune surveillance. Immunological Reviews.
  86. (2005). Cutting Edge: MHC Class II-Restricted Killing In Vivo during Viral Infection.
  87. (2000). Cytotoxic T cell immunity against telomerase reverse transcriptase in humans.
  88. (2004). Cytotoxic T Lymphocyte Therapy for Epstein-Barr Virus+ Hodgkin's Disease.
  89. (1994). Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice.
  90. (2004). DCs and CD40-activated B cells: current and future avenues to cellular cancer immunotherapy. Trends in Immunology.
  91. (2005). Dendritic cell fusion vaccines for cancer immunotherapy.
  92. (2001). Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy.
  93. (2004). Dendritic cell-tumor cell hybrid vaccination for metastatic cancer. Cancer Immunology, Immunotherapy :
  94. (2007). Dendritic cell-tumor fusion vaccine prevents tumor growth in vivo.
  95. (1998). Dendritic cells and the control of immunity.
  96. (2007). Dendritic cells fused with allogeneic breast cancer cell line induce tumor antigen-specific CTL responses against autologous breast cancer cells.
  97. (2005). Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.
  98. (1998). Dendritic cells fused with mastocytoma cells elicit therapeutic antitumor immunity.
  99. (2010). Dendritic cells, T-cells and their possible role in the treatment of leukaemia and lymphoma.
  100. (2007). Dendritic/tumor fusion cell-based vaccination against cancer. Archivum Immunologiae Et Therapiae Experimentalis.
  101. (2006). Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses.
  102. (2007). Design and development of synthetic peptide vaccines: past, present and future. Expert Review of Vaccines.
  103. (2008). Development of a clinical model for ex vivo expansion of multiple populations of effector cells for adoptive cellular therapy.
  104. (1996). Development of tumor B-cell lymphocyte hybridoma (TBH) autovaccination. Results of a phase I-II clinical trial.
  105. (2000). Differential tumor surveillance by natural killer (NK) and NKT cells.
  106. (2005). Diverse CD8+ T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocytemacrophage colony-stimulating factor gene-transduced renal tumor cell vaccine.
  107. (2002). Donor leukocyte infusion from immunized donors increases tumor vaccine efficacy after allogeneic bone marrow transplantation.
  108. (1998). Durability of Complete Responses in Patients With Metastatic Cancer Treated With High-Dose Interleukin-2: Identification of the Antigens Mediating Response. Annals of Surgery.
  109. (2003). Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunology, Immunotherapy :
  110. (1966). Effect of leukocytes on transplantability of human cancer.
  111. (1994). Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells.
  112. (1994). Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colonystimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.
  113. (2001). Electrofusion of a Weakly Immunogenic Neuroblastoma with Dendritic Cells Produces a Tumor Vaccine. Cellular Immunology.
  114. (2003). Electrofusion of syngeneic dendritic cells and tumor generates potent therapeutic vaccine. Cellular Immunology.
  115. (2002). Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination. Cancer Immunology, Immunotherapy :
  116. (1998). Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
  117. (2009). Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer.
  118. (1996). Enhancement of antitumor immunity by CTLA-4 blockade.
  119. (2004). Epstein-Barr virus-specific cytotoxic Tlymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease.
  120. (2000). Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance.
  121. (1970). Established immunoglobulin producing myeloma (IgE) and lymphoblastoid (IgG) cell lines from an IgE myeloma patient. Clinical and Experimental Immunology.
  122. (1991). Evidence for the involvement of CD56 molecules in alloantigen-specific recognition by human natural killer cells.
  123. (2009). Ex vivo expansion of tumor specific lymphocytes with IL-15 and IL-21 for adoptive immunotherapy in melanoma.
  124. (2000). Expression of B7.1 (CD80) in a renal cell carcinoma line allows expansion of tumor-associated cytotoxic T lymphocytes in the presence of an alloresponse.
  125. (1995). Expression of the MAGE gene family in human lymphocytic leukemia. Cancer Immunology, Immunotherapy :
  126. (2007). From cancer immunosurveillance to cancer immunotherapy. Immunological Reviews.
  127. (2004). Function and regulation of MHC class II molecules in T-lymphocytes: of mice and men. Human Immunology.
  128. (2004). Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses.
  129. (2005). Fusion hybrids of dendritic cells and autologous myeloid blasts as a potential cellular vaccine for acute myeloid leukaemia.
  130. (2005). Fusion of dendritic cells with multiple myeloma cells results in maturation and enhanced antigen presentation.
  131. (2000). Fusions of Human Ovarian Carcinoma Cells with Autologous or Allogeneic Dendritic Cells Induce Antitumor Immunity.
  132. (2007). Generation and functional assessment of antigen-specific T cells stimulated by fusions of dendritic cells and allogeneic breast cancer cells.
  133. (2000). Generation and purification of CD8+ melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy.
  134. (2009). Generation in vivo of peptide-specific cytotoxic T cells and presence of regulatory T cells during vaccination with hTERT (class I and II) peptidepulsed DCs.
  135. (2004). Generation of dendritic cell-tumor cell hybrids by electrofusion for clinical vaccine application. Cancer Immunology Immunotherapy.
  136. (1996). Generation of human dendritic cells/Langerhans cells from circulating CD34+ hematopoietic progenitor cells.
  137. (2010). Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and antiCD3/CD28.
  138. (2004). Genomic organization, incidence, and localization of the SPAN-x family of cancer-testis antigens in melanoma tumors and cell lines.
  139. (2007). GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia.
  140. (2007). Graft-versus-leukemia in chronic lymphocytic leukemia.
  141. (2007). Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells.
  142. (1997). Hepatitis B virus, the vaccine, and the control of primary cancer of the liver.
  143. (2007). Hierarchy of the human natural killer cell response is determined by class and quantity of inhibitory receptors for self-HLA-B and HLA-C ligands.
  144. (2005). Highaffinity, peptide-specific T cell receptors can be generated by mutations in CDR1, CDR2 or CDR3.
  145. (2008). HLA class I supertypes: a revised and updated classification.
  146. (2008). HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL.
  147. (2007). HLAG expression in human ovarian carcinoma counteracts NK cell function.
  148. (2003). Homing and cellular traffic in lymph nodes.
  149. (2010). How do tumors actively escape from host immunosurveillance? Archivum Immunologiae Et Therapiae Experimentalis.
  150. (1999). Human antigen-presenting cell/tumour cell hybrids stimulate strong allogeneic responses and present tumour-associated antigens to cytotoxic T cells in vitro.
  151. (2008). Human leukocyte antigen-G and cancer immunoediting.
  152. (2008). Human natural killer cells.
  153. (2002). Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application.
  154. (1996). Human T- and B-cell functions in SCID-hu mice. Seminars in Immunology.
  155. (2000). Hybrid cell vaccination for cancer immune therapy: First clinical trial with metastatic melanoma.
  156. (1998). Hybrid cell vaccination in cancer immunotherapy. Recruitment and activation of T cell help for induction of anti tumour cytotoxic T cells.
  157. (2006). Hybrid cells formed by fusion of Epstein Barr virus-associated B-lymphoblastoid cells and either marrow-derived or solid tumour-derived cell lines display different costimulatory phenotypes and abilities to activate allogeneic T-cell responses in vitro.
  158. (2003). Hybrid-cell vaccines for cancer immune therapy.
  159. (2003). Hybrid-cell vaccines for cancer immune therapy. Molecular Biotechnology.
  160. (2006). Hybrid-primed lymphocytes and hybrid vaccination prevent tumor growth of lewis lung carcinoma in mice.
  161. (1995). Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumorspecific cytotoxic T lymphocyte lines.
  162. (2005). IL-12 and IL-10 expression synergize to induce the immune-mediated eradication of established colon and mammary tumors and lung metastasis.
  163. (2005). IL-2/B7.1 (CD80) fusagene transduction of AML blasts by a self-inactivating lentiviral vector stimulates T cell responses in vitro: a strategy to generate whole cell vaccines for AML. Molecular Therapy.
  164. (1998). IL-4 and CD40 ligation affect differently the differentiation, maturation, and function of human CD34+ cellderived CD1a+CD14- and CD1a-CD14+ dendritic cell precursors in vitro.
  165. (2001). Immune and clinical responses in patients with metastatic melanoma to CD34 (+) progenitor-derived dendritic cell vaccine.
  166. (2009). Immune therapy for cancer.
  167. (2008). Immunemediated dormancy: an equilibrium with cancer.
  168. (2007). Immunity, infection, and cancer.
  169. (2002). Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12.
  170. (2006). Immunoediting of cancers may lead to epithelial to mesenchymal transition.
  171. (2009). Immunohistological analysis of peptide-induced delayed-type hypersensitivity in advanced melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination.
  172. (2009). Immunology : a short course.
  173. (2000). Immunology and immunotherapy of human cancer: present concepts and clinical developments. Critical Reviews in oncology/hematology.
  174. (2006). Immunosuppression in melanoma immunotherapy: potential opportunities for intervention.
  175. (2008). Immunosuppressive mechanisms in human tumors: why we still cannot cure cancer. Immunology Letters.
  176. (2009). Immunosuppressive networks in the tumour environment and their effect in dendritic cells.
  177. (2007). Immunosuppressive strategies that are mediated by tumor cells.
  178. (1969). Immunotherapy and Chemotherapy of Moloney Sarcoma Virusinduced Tumors in Mice.
  179. (2008). Impact of vaccination with Cervarix (trade mark) on subsequent HPV-16/18 infection and cervical disease in women 15-25 years of age. Gynecologic Oncology.
  180. (2003). In vitro dendritic cell-induced T cell responses to B cell chronic lymphocytic leukaemia enhanced by IL-15 and dendritic cell-B-CLL electrofusion hybrids. Clinical and Experimental Immunology.
  181. (2008). In vitro generation of cytotoxic and regulatory T cells by fusions of human dendritic cells and hepatocellular carcinoma cells.
  182. (2008). In vivo anti-tumor effect of hybrid vaccine of dendritic cells and esophageal carcinoma cells on esophageal carcinoma cell line 109 in mice with severe combined immune deficiency.
  183. (2007). In-vitro activation of cytotoxic T lymphocytes by fusion of mouse hepatocellular carcinoma cells and lymphotactin gene-modified dendritic cells.
  184. (1999). Induced immunity by expression of interleukin-2 or GM-CSF gene in murine neuroblastoma cells can generate antitumor response to established tumors. Cancer Gene Therapy.
  185. (2003). Induction of specific antitumor immunity in the mouse with the electrofusion product of tumor cells and dendritic cells. Molecular Therapy.
  186. (2008). Induction of specific cytolytic T lymphocytes using fusions of hepatocellular carcinoma (HCC) patientderived dendritic cells and allogeneic HCC cell line.
  187. (1998). Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients.
  188. (1993). Interleukin 12 and tumor necrosis factor alpha are costimulators of interferon gamma production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist.
  189. (2001). Interleukin-7: master regulator of peripheral T-cell homeostasis. Trends in Immunology.
  190. (2005). Intraepithelial CD8+ tumorinfiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.
  191. (2009). Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities.
  192. (2010). Ipilimumab: attenuation of an inhibitory immune checkpoint improves survival in metastatic melanoma. Expert Review of Anticancer Therapy.
  193. (2010). Leucine-rich repeat protein PRAME: expression, potential functions and clinical implications for leukaemia.
  194. (2010). Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.
  195. (2001). MAGE-A genes are not expressed in human leukemias.
  196. (1998). Major histocompatibility complex expression on human, male germ cells: a review.
  197. (1993). Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients.
  198. (2003). MHC class I antigens, immune surveillance, and tumor immune escape.
  199. (2008). MHC class I assembly: out and about. Trends in Immunology.
  200. (2008). Modulation of the antitumor immune response by complement.
  201. (1998). Molecular mechanisms of lymphocyte homing to peripheral lymph nodes.
  202. (2007). mRNA expression of MAGEA3 gene in leukemia cells.
  203. (2004). MUC1 expression in human prostate cancer cell lines and primary tumors.
  204. (2004). Natural killer cells: biology and clinical use in cancer therapy.
  205. (1998). Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated
  206. (2002). Natural selection of tumor variants in the generation of "tumor escape" phenotypes.
  207. (2002). New aspects of naturalkiller-cell surveillance and therapy of cancer.
  208. (1999). Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism.
  209. (2000). NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway.
  210. (2007). NKT cells in immunoregulation of tumor immunity: a new immunoregulatory axis. Trends in Immunology.
  211. (2003). Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors.
  212. (1977). Origins of human cancer,
  213. (2010). Overview of the immune response.
  214. (2009). Patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells elicit anti-tumor activity: in vitro results and clinical responses.
  215. (2009). Patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells elicit anti-tumor activity: in vitro results and clinical responses. Cancer Immunology, Immunotherapy :
  216. (2002). Peptide-based cancer vaccines. Seminars in Oncology.
  217. (2007). Phase I/II feasibility study evaluating the ___________________________________________________________
  218. (2007). Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma.
  219. (2005). Plasmacytoid dendritic cells (pDC) are the major DC subset innately producing cytokines in human lymph nodes.
  220. (1999). Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon.
  221. (2007). Plasmid DNA and viral vector-based vaccines for the treatment of cancer.
  222. (2010). Polarized dendritic cells as cancer vaccines: Directing effector-type T cells to tumors. Seminars in Immunology.
  223. (1999). Poly(ethylene glycol) (PEG)-mediated fusion between pure lipid bilayers: a mechanism in common with viral fusion and secretory vesicle release.
  224. (1976). Polyethylene glycol-induced mammalian cell hybridization: effect of polyethylene glycol molecular weight and concentration. Somatic Cell Genetics.
  225. (2007). Preclinical development of hybrid cell vaccines for multiple myeloma.
  226. (2008). Preliminary report on tumor stem cell/B cell hybridoma vaccine for recurrent glioblastoma multiforme. Hematology/oncology and Stem Cell Therapy.
  227. Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic/tumor fusion cells.
  228. (2007). Principles of adoptive T cell cancer therapy.
  229. (2001). Progress in human tumour immunology and immunotherapy.
  230. (2004). Progress in the development of immunotherapy of cancer using ex vivo-generated dendritic cells expressing multiple tumor antigen epitopes.
  231. (1996). Protective antitumor immunity induced by immunization with completely allogeneic tumor cells.
  232. (2001). Purified hybrid cells from dendritic cell and tumor cell fusions are superior activators of antitumor immunity.
  233. (2002). Recent advances in vaccine adjuvants.
  234. (1982). Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2.
  235. (2010). Regulation of tumor immunity by tumor/dendritic cell fusions. Clinical & Developmental Immunology.
  236. (2006). Regulatory T cells, tumour immunity and immunotherapy.
  237. (2005). Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells.
  238. (1997). Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors.
  239. (2005). Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer.
  240. (2001). Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunology, Immunotherapy :
  241. (2006). Roadmap to a Better Therapeutic Tumor Vaccine.
  242. (2002). Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma.
  243. (2007). Semi-allogeneic dendritic cells can induce antigen-specific T-cell activation, which is not enhanced by concurrent alloreactivity. Cancer Immunology, Immunotherapy :
  244. (1991). Sequence analysis of peptides bound to MHC class II molecules.
  245. (1999). Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma.
  246. (1997). Signal transduction during natural killer cell activation: inside the mind of a killer.
  247. (2009). Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients.
  248. (2010). Sipuleucel-T immunotherapy for castration-resistant prostate cancer. The New England
  249. (2011). Sipuleucel-T: Prototype for Development of Antitumor Vaccines.
  250. (2004). Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.
  251. (1975). Spontaneous and induced tumor incidence in germfree "nude" mice.
  252. (2010). Strategies for cancer vaccine development.
  253. (2003). Successful adoptive immunotherapy with vaccine-sensitized T cells, despite no effect with vaccination alone in a weakly immunogenic tumor model. Cancer Immunology, Immunotherapy :
  254. (2007). Superior anti-tumor protection and therapeutic efficacy of vaccination with allogeneic and semiallogeneic dendritic cell/tumor cell fusion hybrids for murine colon adenocarcinoma.
  255. (2006). Superior protective and therapeutic effects of IL-12 and IL-18 gene-transduced dendritic neuroblastoma fusion cells on liver metastasis of murine neuroblastoma.
  256. (2003). Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells.
  257. (2005). T cell avidity and tumor recognition: implications and therapeutic strategies.
  258. (2009). T helper 17 cells promote cytotoxic T cell activation in tumor immunity.
  259. (2005). TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance.
  260. (2001). The biology of human natural killer-cell subsets. Trends in Immunology.
  261. (2008). The immunogenicity of the hTERT540-548 peptide in cancer.
  262. (2002). The innate immune response to tumors and its role in the induction of T-cell immunity. Immunological Reviews.
  263. (1993). The role of "indirect" recognition in initiating rejection of skin grafts from major histocompatibility complex class II-deficient mice.
  264. (2002). The role of CD55 in protecting the tumour environment from complement attack. Tissue Antigens.
  265. (2010). The role of CD80/CD86 in generation and maintenance of functional virusspecific CD8+ T cells in mice infected with lymphocytic choriomeningitis virus.
  266. (2002). The roles of IFN gamma in protection against tumor development and cancer immunoediting.
  267. (2004). The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunology, Immunotherapy :
  268. (2010). The specialized iNKT cell system recognizes glycolipid antigens and bridges the innate and acquired immune systems with potential applications for cancer therapy.
  269. (1984). The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma.
  270. (2002). The treatment of patients with disseminated malignant melanoma by vaccination with autologous cell hybrids of tumor cells and dendritic cells.
  271. (2002). Therapeutic immune response induced by electrofusion of dendritic and tumor cells. Cellular Immunology.
  272. (1999). Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte/macrophage colony-stimulating factor genetically modified dendritic cells.
  273. (2010). Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens.
  274. (1992). Three transcriptionally distinct forms of Epstein-Barr virus latency in somatic cell hybrids: cell phenotype dependence of virus promoter usage.
  275. (2005). TLR agonists as vaccine adjuvants:
  276. (2006). Transforming growth factor-beta regulation of immune responses.
  277. (2005). Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma.
  278. (2007). Tumor immunoediting and immunosculpting pathways to cancer progression.
  279. (1992). Tumor immunology: the first century.
  280. (2003). Tumor immunotherapy by converting tumor cells to MHC class II-positive, Ii protein-negative phenotype. Cancer Immunology, Immunotherapy :
  281. (1977). Tumor neutralization, immunotherapy, and chemoimmmunotherapy of a Friend leukemia with cells secondarily sensitized in vitro.
  282. (2003). Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells.
  283. (2002). Tumor___________________________________________________________ Bibliography associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.
  284. (2003). Tumor-derived TGFbeta reduces the efficacy of dendritic cell/tumor fusion vaccine.
  285. (1995). Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer.
  286. (2004). Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma.
  287. (2008). Tumour immunity: effector response to tumour and role of the microenvironment. The Lancet.
  288. (2011). Tumour-associated antigens: considerations for their use in tumour immunotherapy.
  289. (2005). Tumour-dendritic hybrid cell vaccination for the treatment of patients with malignant melanoma: immunological effects and clinical results.
  290. (1988). Two mechanisms for the extinction of gene expression in hybrid cells.
  291. (2007). Unique human tumor antigens: immunobiology and use in clinical trials.
  292. (2005). Vaccination of Dendritic Cells Loaded with Interleukin-12-Secreting Cancer Cells Augments In vivo Antitumor Immunity: Characteristics of Syngeneic and Allogeneic Antigen-Presenting Cell Cancer Hybrid Cells.
  293. (2004). Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12.
  294. (1998). Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells.
  295. (2011). Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma.
  296. (2008). Vaccines against cervical cancer.
  297. (2010). WT-1 expression in gastrointestinal stromal tumours.
  298. (2010). WT1 mutation in 470 adult patients with acute myeloid ___________________________________________________________ Bibliography leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system.
  299. (2010). WT1 protein is a transcriptional activator of the antiapoptotic bag3 gene.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.